Differencial proteome of clear-cell renal cell carcinoma (ccRCC) tissues

被引:2
|
作者
Vieira de Ribeiro, Ana Julia [1 ]
Sandim, Vanessa [1 ]
Ornellas, Antonio Augusto [2 ,3 ]
Reis, Rodrigo Siqueira [4 ]
Domont, Gilberto [4 ]
Alves, Gilda [1 ]
机构
[1] Inst Nacl Canc, Appl Genet Lab, Div Hematol, BR-20230130 Rio De Janeiro, RJ, Brazil
[2] Inst Nacl Canc, Div Urol, BR-20230130 Rio De Janeiro, RJ, Brazil
[3] Hosp Mario Kroeff, Div Urol, Rio De Janeiro, RJ, Brazil
[4] Univ Fed Rio de Janeiro, Inst Chem, Prote Unit, BR-21941 Rio De Janeiro, RJ, Brazil
来源
INTERNATIONAL BRAZ J UROL | 2013年 / 39卷 / 01期
关键词
Carcinoma; Renal Cell; Proteome; Electrophoresis; Polyacrylamide Gel; Kidney; OXIDATIVE STRESS; MESSENGER-RNA; CANCER-CELLS; IDENTIFICATION; EXPRESSION; PROHIBITIN; BIOMARKER;
D O I
10.1590/S1677-5538.IBJU.2013.01.11
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We attempted to detect, for the first time in a Brazilian cohort, differences in protein expression between clear-cell renal cell carcinoma (ccRCC) and their normal adjacent tissues, aiming to identify biomarkers and/or therapeutic target candidates for this disease. Material and Methods: Twenty-four ccRCC and adjacent normal tissues were collected after surgery and their protein extracts were quantified, pooled and separated by two-dimensional polyacrylamide gel electrophoresis (2DE), followed by statistical analysis of the stained gels. Spots of interest were excised from the gels, digested with trypsin and identified by MALDI-TOF-TOF mass spectrometry. Results: Twenty-six differential spots were detected between the two classes of tissues, among which twenty were identified by mass spectrometry and sixteen were found to be non-redundant. Eleven proteins were either underexpressed or undetected in the ccRCC extracts, such as prohibitin and peroxiredoxin-3, whereas five were found to be overexpressed or exclusively detected in the ccRCC extract, including alpha beta crystalin and heat shock protein 27. Conclusions: Several proteins were detected at differential levels when compared to normal adjacent tissues, and, moreover, many have been previously described by their relationship with RCC. Therefore, this work corroborates previous reports on the search for biomarkers for ccRCC, as well as it points out new candidates that may be validated in future studies.
引用
收藏
页码:83 / 94
页数:12
相关论文
共 50 条
  • [21] Integrated molecular analysis of clear-cell renal cell carcinoma
    Yusuke Sato
    Tetsuichi Yoshizato
    Yuichi Shiraishi
    Shigekatsu Maekawa
    Yusuke Okuno
    Takumi Kamura
    Teppei Shimamura
    Aiko Sato-Otsubo
    Genta Nagae
    Hiromichi Suzuki
    Yasunobu Nagata
    Kenichi Yoshida
    Ayana Kon
    Yutaka Suzuki
    Kenichi Chiba
    Hiroko Tanaka
    Atsushi Niida
    Akihiro Fujimoto
    Tatsuhiko Tsunoda
    Teppei Morikawa
    Daichi Maeda
    Haruki Kume
    Sumio Sugano
    Masashi Fukayama
    Hiroyuki Aburatani
    Masashi Sanada
    Satoru Miyano
    Yukio Homma
    Seishi Ogawa
    Nature Genetics, 2013, 45 : 860 - 867
  • [22] Re: Sorafenib in advanced clear-cell renal cell carcinoma
    Karakiewicz, Pierre I.
    Hutterer, Georg
    EUROPEAN UROLOGY, 2007, 52 (01) : 279 - 280
  • [23] Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma
    Vuong, Lynda
    Kotecha, Ritesh R.
    Voss, Martin H.
    Hakimi, A. Ari
    CANCER DISCOVERY, 2019, 9 (10) : 1349 - 1357
  • [24] Obesity, Cholesterol, and Clear-Cell Renal Cell Carcinoma (RCC)
    Drabkin, Harry A.
    Gemmill, Robert M.
    ADVANCES IN CANCER RESEARCH, VOL 107, 2010, 107 : 39 - 56
  • [25] Integrated molecular analysis of clear-cell renal cell carcinoma
    Sato, Yusuke
    Yoshizato, Tetsuichi
    Shiraishi, Yuichi
    Maekawa, Shigekatsu
    Okuno, Yusuke
    Kamura, Takumi
    Shimamura, Teppei
    Sato-Otsubo, Aiko
    Nagae, Genta
    Suzuki, Hiromichi
    Nagata, Yasunobu
    Yoshida, Kenichi
    Kon, Ayana
    Suzuki, Yutaka
    Chiba, Kenichi
    Tanaka, Hiroko
    Niida, Atsushi
    Fujimoto, Akihiro
    Tsunoda, Tatsuhiko
    Morikawa, Teppei
    Maeda, Daichi
    Kume, Haruki
    Sugano, Sumio
    Fukayama, Masashi
    Aburatani, Hiroyuki
    Sanada, Masashi
    Miyano, Satoru
    Homma, Yukio
    Ogawa, Seishi
    NATURE GENETICS, 2013, 45 (08) : 860 - U191
  • [26] Dystroglycan expression in clear-cell type renal cell carcinoma
    Camerini, A.
    De Luca, F.
    Genovese, G.
    De Paola, B.
    Valsuani, C.
    Tartarelli, G.
    Donati, S.
    Rettino, A.
    Cittadini, A.
    Sgambato, A.
    Gentili, C.
    Amoroso, D.
    ANNALS OF ONCOLOGY, 2006, 17 : XI34 - XI35
  • [27] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02): : 125 - 134
  • [28] Sorafenib treatment of clear-cell renal cell carcinoma (CCRCC) and colorectal carcinoma (CRC) cells: Differential effects on gene expression and cell death pathways
    Vaziri, S. A.
    Al-Hazzouri, A.
    Grabowski, D. R.
    Ganapathi, M. K.
    Bukowski, R. M.
    Ganapathi, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)?
    Basso, Umberto
    Maruzzo, Marco
    Fraccon, Anna Paola
    Sava, Teodoro
    Massari, Francesco
    Sacco, Cosimo
    Valcamonico, Francesca
    Maines, Francesca
    Lo Re, Giovanni
    Donati, Donatella
    Baier, Susanne
    Durante, Emilia
    Soraru', Mariella
    Nicodemo, Maurizio
    Bearz, Alessandra
    Sartori, Donata
    Fiduccia, Pasquale
    Zustovich, Fable
    Pasini, Felice
    Zagonel, Vittorina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [30] Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
    Johns, Andrew
    Campbell, Matthew T.
    Gao, Mamie
    Lim, Zita Dubauskas
    Wang, Emily
    Hahn, Andrew Warren
    Gao, Jianjun
    Shah, Amishi Yogesh
    Msaouel, Pavlos
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 419 - 419